Condition 1: Glanzmann thrombasthenia. Condition 2: Von Willebrand. Qualitative platelet defects Von Willebrand disease
Conditions
Interventions
Intervention 1: for six months, patients treated with tranexamic acid capsules manufactured by Amin-drug, daily 25 mg per kilogram of body up to 500 mg placed in a single dose. Intervention 2: for six
Treatment - Drugs
Placebo
for six months, patients treated with tranexamic acid capsules manufactured by Amin-drug, daily 25 mg per kilogram of body up to 500 mg placed in a single dose
for six months use tranexamic acid capsules that filled with starch as placebo
Sponsors
Vice Chancellor for research of Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 139 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: All patients with a von Willebrand I, II, III and Glanzmann thrombasthenia which they records are included in Arak Amir-Kabir Hospital.; Exclusion criteria: (a)Patients who have a history of thrombosis; (b)Patients who do not consent to the inclusion; (c)Patients with hepatitis B or C; (d)Patients with liver or renal dysfunction; (e)Patients with local bleeding lesions such as hemangiomas or local wound; (f)Younger than 2 years; (g)Patients who can not tolerate the gastrointestinal drug;
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of bleeding attacks. Timepoint: before and six months after intervention. Method of measurement: counting frequency.;The severity of bleeding. Timepoint: before and six months after intervention. Method of measurement: visual scale and assigned a grade from one to four.;The number of used concentrates. Timepoint: before and six months after intervention. Method of measurement: counting frequency. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Laura Melikof
Arak University of Medical Sciences
Outcome results
None listed